Virtual Library

Start Your Search

Z. Wang



Author of

  • +

    P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Localized Disease - NSCLC
    • Presentations: 1
    • +

      P2.02-035 - Is There an Optimal Time to Initiate Adjuvant Chemotherapy in Order to Predict the Benefit of Survival in Non-Small Cell Lung Cancer? (ID 2341)

      09:30 - 09:30  |  Author(s): Z. Wang

      • Abstract
      • Slides

      Background:
      Adjuvant chemotherapy (ACT) improves the survival for completely resected non-small cell lung cancer (NSCLC) patients. However, there are very few reports to explore the correlation between time of initiation of adjuvant chemotherapy (TTAC) and survival.

      Methods:
      208 completely resected NSCLC patients received adjuvant chemotherapy in Cancer Hospital, Chinese Academy of Medical Sciences from 2001-2010 were analyzed. TTAC was measured from the date of surgery to initiation of ACT. Disease-free survival (DFS) was defined as the duration from the surgery to the time of relapse or last follow-up. Optimal cutoff value of the TTAC was determined by maximally selected log-rank statistics. Survival analysis was performed using Kaplan–Meier estimates, log-rank tests and Cox’s proportional hazards regression analysis. Propensity score matching (PSM) was used, and a survival analysis of the match data was carried out.

      Results:
      The best discriminating cutoff value of TTAC was the 50th day(Figure 2). According to the cutoff value of 50, patients were divided into 2 groups, group1 (≤50days, n=183) and group2 (>50 days, n=25). Figure 1 shows the baseline characteristics of the two groups of patients before and after PSM .There was significant difference in DFS between the two groups (mDFS: 737days vs. 369days, P=0.005)(Figure 2), and the TTAC was found to be a significant predictive factor for DFS in multivariable analysis (P =0.035).Unfortunately, DFS was not continually significant difference in 22 PSM pairs (mDFS:576days vs. 369days,P=0.122) (Figure 2).Figure 1Figure 2





      Conclusion:
      TTAC does not appear to be associated with DFS in NSCLC. The conclusion was limited by the small sample size; therefore the number of patients between the groups was not close. Larger sample of cases should be warranted in future.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P3.01-061 - A Prognostic Model for Platinum-Doublet Regimens as Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (ID 1228)

      09:30 - 09:30  |  Author(s): Z. Wang

      • Abstract
      • Slides

      Background:
      Poor prognosis of advanced non-small-cell lung cancer (NSCLC) patients and the promising therapeutic effect of platinum urge the oncologists to evaluate the role of platinum-doublet as second-line chemotherapy and establish the definition of platinum sensitivity in NSCLC.

      Methods:
      We retrospectively analyzed 364 advanced NSCLC patients who received platinum-doublet regimens as second-line chemotherapy after platinum-based first-line treatment. Patients were divided into four groups by their time-to-progression (TTP) after first-line chemotherapy: 0-3, 4-6, 7-12, and >12months group, respectively. Treatment efficacy of patients’ overall survival (OS), progression-free survival (PFS) and response rate (RR), as well as treatment-related toxicity, were compared among the four groups. A prognosis score system was established by Cox proportional hazard model.

      Results:
      All patients had Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. As part of the platinum-doublet regimen,145(39.8%) patients received taxol, 81(22.3%) received gemcitabine, 99(27.2%) received pemetrexed, 32(8.8%) received vinorelbine, 4(1.1%) received etoposide, and 3(0.8%) received irinotecan. The most frequent grade 3/4 toxicity was neutropenia (20.1%) and nausea/vomiting (3.3%).The median follow-up time was 11.0 months. Patients with TTP> 12 months had significant longer survival than the rest of the group after second-line platinum-rechallenge (HR, 0.809; 95% CI: 0.703-0.931;P=0.003).Prognostic score (TAF score) was calculated by adding 1 point each for any of the following: TTP>12 months, age≤60 years, and female, all of which were independent prognostic factors for patient survival (P=0.015, P=0.002, P=0.012, respectively). Median OS were equal to 25.0, 16.0 and 11.0 months for best (2-3 points), intermediate (1 point) and worst (0 point) category, respectively (P<0.0001, Figure 1). Figure 1 Kaplan–Meier curves of overall survival according to patients’ TAF Score. After second-line platinum-based chemotherapy, patients with a TAF Score of 2-3 had significant better survival than those scored 0 or 1 (P<0.0001). Figure 1



      Conclusion:
      A TAF score of 2 or 3 points indicates a good prognosis if advanced NSCLC patients received platinum-rechallenge after disease progression.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 211)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Localized Disease - NSCLC
    • Presentations: 1
    • +

      P3.02-032 - Effect of Age on Adjuvant Chemotherapy after Resection of Non-Small Cell Lung Cancer (ID 2343)

      09:30 - 09:30  |  Author(s): Z. Wang

      • Abstract
      • Slides

      Background:
      Adjuvant chemotherapy (ACT) improves the survival for completely resected non-small cell lung cancer (NSCLC) patients. However, there are few reports to explore the effect of age on the efficacy of adjuvant chemotherapy of NSCLC after surgery.

      Methods:
      Patients received adjuvant chemotherapy after surgery in Cancer Hospital, Chinese Academy of Medical Sciences from 2001-2010 were analyzed. Disease Free Survival (DFS) of the two groups of patients was compared in terms of their age. Survival analysis was performed using Kaplan–Meier estimates, log-rank tests and Cox’s proportional hazards regression analysis. Propensity score matching (PSM) was used, and a survival analysis of the match data was carried out.

      Results:
      The data of 256 patients with stage I to stage Ⅲ NSCLC who underwent completely resection was analyzed. Those two groups,patients aged≤65 years (27~65, n=206) and patients aged>65 years (66~72, n=50) ,were compared. Figure 1 shows the baseline characteristics of the two groups of patients before and after PSM. There was no significant difference in DFS between the two groups (mDFS: 594 days vs. 554 days, P=0.951) (Figure 2), and the age was not associated with DFS in multivariable analysis (P =0.602). DFS was continually not significant difference in 40 PSM pairs (mDFS: 600 days vs. 554 days, P=0.731) (Figure 2).Figure 1Figure 2





      Conclusion:
      The results suggest that older patients do not appear a shorter DFS than younger. Thus, elderly patients should not be denied adjuvant chemotherapy based merely on age. The conclusion was limited by the small sample size; moreover, the number of patients between the groups was not close. Larger sample of cases should be warranted in future.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.